Financial Ratios INVO Bioscience, Inc.
Equities
INVO
US44984F4019
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6855 USD | +0.37% | +2.58% | -48.52% |
08-14 | Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Loss $-0.62 Per Share | MT |
08-14 | Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Revenue $1.8M | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -82.32 | -54.1 | -30.45 | -91.17 | -33.85 | |||||
Return on Total Capital | 37.92 | -211.33 | -40.88 | -119.44 | -75.1 | |||||
Return On Equity % | 67.34 | -822.59 | -101.96 | -343.99 | 18.95K | |||||
Return on Common Equity | 67.34 | -822.59 | -101.96 | -343.99 | 264.09 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 90.56 | 92.38 | 96.96 | 65.1 | 35.96 | |||||
SG&A Margin | 205.03 | 584.71 | 216.7 | 1.29K | 247.85 | |||||
EBITDA Margin % | -113.74 | -530.52 | -124.73 | -1.28K | -217.38 | |||||
EBITA Margin % | -114.16 | -531.5 | -125.35 | -1.29K | -224.04 | |||||
EBIT Margin % | -114.47 | -531.67 | -125.39 | -1.29K | -224.04 | |||||
Income From Continuing Operations Margin % | -146.43 | -804.73 | -159.97 | -1.32K | -266 | |||||
Net Income Margin % | -146.43 | -804.73 | -159.97 | -1.32K | -266 | |||||
Net Avail. For Common Margin % | -146.43 | -804.73 | -159.97 | -1.32K | -266 | |||||
Normalized Net Income Margin | -87.54 | -502.95 | -102.3 | -827.79 | -160.44 | |||||
Levered Free Cash Flow Margin | -150.84 | -103.25 | -27.89 | -305.75 | 21.24 | |||||
Unlevered Free Cash Flow Margin | -157.63 | -172.79 | -37.44 | -307.63 | 16.55 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.15 | 0.16 | 0.39 | 0.11 | 0.24 | |||||
Fixed Assets Turnover | 12.91 | 5.1 | 3.03 | 0.34 | 0.69 | |||||
Receivables Turnover (Average Receivables) | 12.68 | 70.91 | 115.29 | 12.89 | 27.75 | |||||
Inventory Turnover (Average Inventory) | 1.93 | 0.43 | 0.46 | 1.04 | 7.33 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.03 | 4.61 | 5.03 | 0.18 | 0.15 | |||||
Quick Ratio | 0.83 | 4.42 | 4.58 | 0.05 | 0.05 | |||||
Operating Cash Flow to Current Liabilities | 0.91 | -2.09 | -4.81 | -1.94 | -0.58 | |||||
Days Sales Outstanding (Average Receivables) | 28.78 | 5.16 | 3.17 | 28.33 | 13.15 | |||||
Days Outstanding Inventory (Average Inventory) | 189.33 | 849.2 | 799.11 | 350.71 | 49.82 | |||||
Average Days Payable Outstanding | 857.92 | 446.86 | 947.73 | 1.24K | 346.96 | |||||
Cash Conversion Cycle (Average Days) | -639.8 | 407.51 | -145.45 | -865.96 | -283.99 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | -12.32 | 13.49 | 29.05 | -272.52 | 972.59 | |||||
Total Debt / Total Capital | -14.05 | 11.89 | 22.51 | 157.96 | 90.68 | |||||
LT Debt/Equity | -11.74 | 1.02 | 26.01 | -170.82 | 758.95 | |||||
Long-Term Debt / Total Capital | -13.39 | 0.9 | 20.16 | 99.01 | 70.76 | |||||
Total Liabilities / Total Assets | 306.83 | 47.54 | 30.15 | 123.82 | 95.73 | |||||
EBIT / Interest Expense | -4.47 | -1.94 | -4.12 | -178.76 | -7.31 | |||||
EBITDA / Interest Expense | -4.39 | -1.93 | -4.08 | -177.46 | -7.09 | |||||
(EBITDA - Capex) / Interest Expense | -4.69 | -1.95 | -4.41 | -177.64 | -7.57 | |||||
Total Debt / EBITDA | -0.27 | -0.14 | -0.41 | -0.25 | -1.32 | |||||
Net Debt / EBITDA | 0.47 | 1.7 | 0.69 | -0.24 | -1.29 | |||||
Total Debt / (EBITDA - Capex) | -0.26 | -0.14 | -0.38 | -0.25 | -1.24 | |||||
Net Debt / (EBITDA - Capex) | 0.44 | 1.69 | 0.64 | -0.24 | -1.21 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % |